CORDRAN OINTMENT Rx
Generic Name and Formulations:
Indications for CORDRAN OINTMENT:
Adults and Children:
Apply thin film to affected areas 2–3 times daily; discontinue when control is achieved. Do not occlude.
Tape: Serum-exuding lesions. Intertrigo.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis or on pre-existing skin atrophy. Avoid tight-fitting diapers or plastic pants. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Use lowest effective dose and potency (esp. in children). Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infections, skin atrophy, striae, miliaria; HPA axis suppression (esp. in children).
Crm 0.025%, 0.05%—120g; Oint 0.05%—60g, 120g; Lotion—15mL, 60mL, 120mL; Tape (roll) 3in x 24in, 3in x 80in—1
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds